40
Participants
Start Date
August 31, 2008
Primary Completion Date
April 30, 2010
Study Completion Date
June 30, 2010
TLN-4601
14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
Sloan-Kettering Institute for Cancer Research, New York
Duke University, Durham
Ottawa Health Research Institute, Ottawa
The Pencer Brain Tumor Center, Princess Margaret Hospital, Toronto
Hôpital Notre-Dame du CHUM, Montreal
Royal Victoria Hospital, Montreal
L'Hotel-Dieu de Quebec, Québec
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke
Lead Sponsor
Thallion Pharmaceuticals
INDUSTRY